Bayer and Onyx Report Phase 3 Study Results of NEXAVAR® (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Research and Markets: Concise Analysis of the International Orphan Drugs Industry
Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan
Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion
GreenLight Biosciences Announces New Partnership with Bayer CropScience
The markets took a stream of negative news and weak economic growth indicators in stride during the first quarter.
Mallinckrodt's lack of scale and weak branded business keep it from earning a moat.
Regulatory issues that we believe have little impact on Novo Nordisk's long-run prospects have finally helped shares of the leading insulin maker go on sale.